Jim Simons Bolt Biotherapeutics, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$0.4 - $0.62 $4,840 - $7,502	12,100 Added 4.01%	314,139 $125,000
Q4 2024 Feb 13, 2025	BUY	$0.5 - $0.68 $4,000 - $5,440	8,000 Added 2.72%	302,039 $166,000
Q3 2024 Nov 13, 2024	BUY	$0.58 - $0.75 $10,034 - $12,975	17,300 Added 6.25%	294,039 $191,000
Q2 2024 Aug 09, 2024	SELL	$0.73 - $1.5 $175,855 - $361,347	-240,898 Reduced 46.54%	276,739 $207,000
Q1 2024 May 13, 2024	BUY	$1.01 - $1.4 $73,087 - $101,309	72,364 Added 16.25%	517,637 $725,000
Q4 2023 Feb 13, 2024	BUY	$0.85 - $1.12 $111,421 - $146,814	131,084 Added 41.72%	445,273 $499,000
Q3 2023 Nov 14, 2023	SELL	$0.98 - $1.46 $166,355 - $247,835	-169,750 Reduced 35.08%	314,189 $327,000
Q2 2023 Aug 11, 2023	BUY	$1.27 - $1.95 $34,544 - $53,040	27,200 Added 5.96%	483,939 $619,000
Q1 2023 May 12, 2023	BUY	$1.29 - $1.66 $19,608 - $25,232	15,200 Added 3.44%	456,739 $635,000
Q4 2022 Feb 13, 2023	BUY	$1.26 - $1.51 $60,078 - $71,998	47,681 Added 12.11%	441,539 $574,000
Q3 2022 Nov 14, 2022	SELL	$1.48 - $2.61 $214,178 - $377,706	-144,715 Reduced 26.87%	393,858 $583,000
Q2 2022 Aug 12, 2022	BUY	$1.41 - $2.91 $350,346 - $723,056	248,473 Added 85.65%	538,573 $1.1 Million
Q1 2022 May 13, 2022	BUY	$2.74 - $4.82 $551,288 - $969,784	201,200 Added 226.32%	290,100 $795,000
Q4 2021 Feb 11, 2022	BUY	$4.19 - $13.97 $40,224 - $134,112	9,600 Added 12.11%	88,900 $436,000
Q3 2021 Nov 12, 2021	BUY	$11.15 - $18.6 $209,954 - $350,238	18,830 Added 31.14%	79,300 $1 Million
Q2 2021 Aug 13, 2021	BUY	$15.4 - $31.46 $931,238 - $1.9 Million	60,470 New	60,470 $935,000

Others Institutions Holding BOLT

# of Institutions

Shares Held

706K

Call Options Held

Put Options Held

View Full List

About Bolt Biotherapeutics, Inc.

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $207M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

More about BOLT

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account